Equities
Health CareHealth Care Equipment & Services
  • Price (USD)118.05
  • Today's Change-0.69 / -0.58%
  • Shares traded1.34m
  • 1 Year change+8.77%
  • Beta0.7436
Data delayed at least 15 minutes, as of Feb 25 2021 17:08 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

  • Revenue in USD (TTM)27.93bn
  • Net income in USD2.86bn
  • Incorporated2014
  • Employees90.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MDT:NYQ since
announced
Transaction
value
Avenu Medical IncAnnounced30 Sep 202030 Sep 2020Announced14.96%--
Companion Medical IncAnnounced11 Aug 202011 Aug 2020Announced17.60%--
Medicrea International SADeal completed15 Jul 202015 Jul 2020Deal completed24.72%134.91m
Data delayed at least 15 minutes, as of Feb 25 2021 17:08 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zimmer Biomet Holdings Inc7.02bn-138.90m34.02bn20.00k--2.7938.004.84-0.691-0.69133.8858.740.28640.87384.99351,225.00-0.56021.15-0.63841.2969.9270.65-1.963.821.034.280.399866.54-12.003.21-112.27---1.161.76
DexCom, Inc.1.93bn493.60m39.01bn5.50k81.2721.3469.5820.254.994.9919.7719.010.57643.515.39350,309.1014.775.7817.296.7867.7166.0925.627.985.194.720.48520.0030.5436.81388.23--42.98--
Baxter International Inc11.67bn1.10bn39.66bn50.00k36.834.5620.523.402.132.1322.5817.210.6113.945.88233,460.005.8110.837.0313.3139.7141.889.5117.191.9511.650.415120.452.743.2136.5622.90-4.89-5.54
Align Technology, Inc.2.47bn1.78bn45.20bn14.53k25.5313.9826.8218.2922.4522.4531.2441.010.67445.644.09--48.4529.3270.5642.4471.3373.2871.8433.471.29------2.7123.93301.0865.27----
Edwards Lifesciences Corp4.39bn823.40m52.74bn14.90k65.4411.5356.6712.021.291.296.947.330.63921.508.29294,382.6012.0014.6913.8117.4875.3674.5118.7721.522.56--0.11510.000.880911.96-21.5610.7230.77--
Boston Scientific Corporation9.91bn-115.00m56.02bn38.00k--3.6555.635.65-0.0815-0.08156.9810.820.32322.405.90260,894.70-0.26743.03-0.31063.7864.5969.70-0.82717.171.45127.130.37370.00-7.665.80-119.23--0.3484--
Becton Dickinson and Co18.21bn1.51bn71.68bn72.00k47.422.9119.453.945.205.2063.4884.880.34133.518.19252,875.003.002.433.442.7746.3046.948.796.780.95766.550.419580.41-1.0010.73-25.681.995.055.66
Intuitive Surgical, Inc.4.36bn1.06bn89.31bn8.08k86.219.1865.6720.498.808.8036.2282.680.4172.506.75539,339.2010.2113.9911.3115.5965.6568.8424.4828.806.24--0.000.00-2.6812.82-23.1112.4933.35--
Stryker Corporation14.35bn1.60bn93.61bn43.00k59.237.1538.826.524.204.2037.8534.790.4451.605.13333,744.204.967.325.818.7263.8165.6911.1413.781.23--0.516839.73-3.587.61-23.242.1312.5216.25
Medtronic PLC27.93bn2.86bn159.83bn90.00k56.193.1528.755.722.112.1420.6637.670.29382.324.87310,288.903.024.663.415.2164.1869.0610.2815.101.749.750.373256.43-5.387.371.7912.0616.2612.10
Thermo Fisher Scientific Inc.32.22bn6.38bn180.99bn75.00k28.615.2520.805.6215.9615.9680.7087.070.50574.356.03--10.016.4611.497.3150.0746.5819.7914.501.7416.100.38657.8126.1413.6972.1126.3428.377.21
Abbott Laboratories34.61bn4.50bn216.80bn109.00k48.656.6127.716.262.522.5119.3818.510.49293.215.85317,504.606.404.197.674.9156.7557.1112.999.251.3011.040.362378.938.4811.1424.8811.5314.428.45
Data as of Feb 25 2021. Currency figures normalised to Medtronic PLC's reporting currency: US Dollar USD

Institutional shareholders

30.87%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2020105.40m7.83%
BlackRock Fund Advisorsas of 31 Dec 202068.55m5.09%
SSgA Funds Management, Inc.as of 31 Dec 202055.93m4.16%
Massachusetts Financial Services Co.as of 31 Dec 202050.41m3.75%
Wellington Management Co. LLPas of 31 Dec 202038.65m2.87%
Lazard Asset Management LLCas of 31 Dec 202024.04m1.79%
Geode Capital Management LLCas of 31 Dec 202021.03m1.56%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 202020.54m1.53%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 202015.78m1.17%
Managed Account Advisors LLCas of 31 Dec 202015.14m1.13%
More ▼
Data from 31 Dec 2020 - 31 Dec 2020Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.